"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 2 | 3 |
| 2002 | 6 | 1 | 7 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 4 | 5 |
| 2005 | 1 | 5 | 6 |
| 2006 | 6 | 3 | 9 |
| 2007 | 4 | 2 | 6 |
| 2008 | 6 | 8 | 14 |
| 2009 | 3 | 1 | 4 |
| 2010 | 3 | 3 | 6 |
| 2011 | 8 | 6 | 14 |
| 2012 | 3 | 5 | 8 |
| 2013 | 8 | 3 | 11 |
| 2014 | 12 | 8 | 20 |
| 2015 | 10 | 4 | 14 |
| 2016 | 6 | 2 | 8 |
| 2017 | 8 | 2 | 10 |
| 2018 | 9 | 5 | 14 |
| 2019 | 3 | 5 | 8 |
| 2020 | 7 | 3 | 10 |
| 2021 | 4 | 3 | 7 |
| 2022 | 2 | 2 | 4 |
| 2023 | 1 | 3 | 4 |
| 2024 | 5 | 2 | 7 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Methylated Arginine Metabolites as Biomarkers for Clinical Status and Response to Type 5 Phosphodiesterase Inhibition in Patients With Fontan Circulation. J Am Heart Assoc. 2025 Apr; 14(7):e038061.
-
How I treat patients with AML using azacitidine and venetoclax. Blood. 2025 Mar 20; 145(12):1237-1250.
-
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025 Mar 13; 145(11):1126-1135.
-
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood. 2025 Mar 06; 145(10):1047-1060.
-
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025 Feb 11; 9(3):617-626.
-
Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models. Blood Adv. 2025 Feb 11; 9(3):473-487.
-
Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia. Blood Cancer Discov. 2025 Jan 08; 6(1):23-37.
-
FT538, iPSC-derived NK cells, enhance AML cell killing when combined with chemotherapy. J Cell Mol Med. 2025 Jan; 29(1):e70169.
-
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia. Haematologica. 2025 Jan 01; 110(1):78-91.
-
An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup. Sci Transl Med. 2025 Jan; 17(779):eadr2012.